UCB SA (LON:0NZT)

Market Cap	41.06B
Revenue (ttm)	5.87B
Net Income (ttm)	1.14B
Shares Out	n/a
EPS (ttm)	5.89
PE Ratio	35.96
Forward PE	27.52
Dividend	0.83 (0.35%)
Ex-Dividend Date	Apr 25, 2025

Volume	13,275
Average Volume	95,014
Open	237.75
Previous Close	244.32
Day's Range	237.50 - 241.40
52-Week Range	129.35 - 263.20
Beta	0.22
RSI	62.49
Earnings Date	Feb 26, 2026

About UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spra...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1925
• Employees: 9,378
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0NZT

Financial Performance

In 2024, UCB SA's revenue was 6.15 billion, an increase of 18.72% compared to the previous year's 5.18 billion. Earnings were 1.07 billion, an increase of 210.50%.

Financial numbers in EUR